Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma

Odontology ◽  
2008 ◽  
Vol 96 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Yutaka Yamazaki ◽  
Itsuo Chiba ◽  
Makoto Ishikawa ◽  
Chiharu Satoh ◽  
Ken-ichi Notani ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Indicator ◽  
P53 Antibodies ◽  
Serum P53 Antibodies ◽  
Serum P53

PS02.052: AUTO-ANTIBODIES AGAINST TUMOR ANIGENS ARE USEFUL BIOMARKERS IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 135-135
Author(s):  
Hideaki Shimada ◽  
Satoshi Yajima ◽  
Yoko Oshima ◽  
Masaaki Ito ◽  
Tatsuki Nanami ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Antibody Titer ◽  
Squamous Cell ◽  
Tumor Antigens ◽  
Healthy Controls ◽  
P53 Antibodies ◽  
Serum P53 Antibodies ◽  
Serum P53

Abstract Background Serum antibodies are induced even ata the eraly phase of carcinogenesis. Serum p53 antibodies (s-p53-Abs) have been developed and approved as routine blood test for monitoring esophageal squamous cell carcinoma (SCC). Recently, we have developed new ELISA systems to detect serum anti-IgG auto-antibodies against tumor antigens in patients with esophageal (SCC). In this paper, we focused on serum auto-antibodies against p53, NY-ESO-1, Galectin-1 and RalA. Methods Serum samples of patients with esophageal SCC were obtained before surgery. Serum anti-IgG antibodies against several tumor antigens were analyzed by newly developed ELISA systems. Target tumor antigens were p53, NY-ESO-1, Galectin-1 and RalA. Cut-off values were fixed using mean + 3SD of values of a total of 74 healthy controls. Changing pattern of serum p53 antibodies titers was also assessed during postoperative follow-up. Results Positive rates of serum antibodies were 18% for p53, 31% for NY-ESO-1, 10% for Galectin-1 and 9% for RalA. Positive rates of these antibodies in healthy controls were 0%. Combination assay improved positive rates without increased false positive rates as follows; p53 + NY-ESO-1 = 40%, p53 + NY-ESO-1 + Galectin-1 = 47%, p53 + NY-ESO-1 + Galectin-1 + RalA = 51%. Although some patients with extremely-high antibody titer for p53 persistently positive even after curative surgery, changing patterns of serum titers seemed to be associated with clinical outcome. Conclusion Although antibody titer of s-p53-Abs seemed to be associated with tumor burden, the titer gradually decresed at the last several months of the terminal stage. Such independent changing pattern of serum autoantibodies may have adding information to conventinal serum markers. We have developed new ELISA system to detect serum autoantibodies for patients with esophageal SCC. Although the positive rates of single serum auto-antibody were still relatively low, combination assay with plural auto-antibodies may be useful. Disclosure All authors have declared no conflicts of interest.

scholarly journals Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma

2008 ◽  
Vol 14 (25) ◽  
pp. 4082 ◽  
Author(s):  
Hong-Yi Cai ◽  
Xiao-Hu Wang ◽  
Ying Tian ◽  
Li-Ying Gao ◽  
Li-Juan Zhang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Significance ◽  
Squamous Cell ◽  
P53 Antibodies ◽  
Serum P53 Antibodies ◽  
Serum P53

scholarly journals Stromal fibers in oral squamous cell carcinoma: A possible new prognostic indicator?

2016 ◽  
Vol 20 (3) ◽  
pp. 405 ◽  
Author(s):  
Priyanka Kardam ◽  
Monica Mehendiratta ◽  
Shweta Rehani ◽  
Madhumani Kumra ◽  
Khushboo Sahay ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Indicator

scholarly journals Expression of RAD51 and Its Clinical Impact in Oral Squamous Cell Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Yuyang Li ◽  
Jia Li ◽  
Jingchun Sun ◽  
Yingkun Liu ◽  
Dingkun Liu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Normal Skin ◽  
Clinical Stage ◽  
Prognostic Indicator ◽  
Normal Mucosa ◽  
Strong Positive Correlation ◽  
Tissue Samples

Purpose. To examine the expression of RAD51 in oral squamous cell carcinoma (OSCC) and analyze its connection with pathological grade, clinical stage, and lymphatic metastasis potential. Methods. For this study, 74 OSCC samples, 15 normal mucosa tissues, and 11 normal skin tissue samples were collected. RAD51 expression was investigated using immunohistochemistry. A follow-up visit was used to assess the prognosis of each patient. We compared RAD51 expression in oral mucosa epithelial cells (OMECs), keratinocytes, and tongue squamous cell carcinoma cells (TSCCs) by Western blot analysis. Results. RAD51 expression was higher in tumor cells than in normal mucosal tissues. In addition, RAD51 expression was associated with higher tumor differentiation (P<0.05). Also, RAD51 expression was higher (P<0.05) in patients with lymphatic metastases, and relapse rates were also higher in patients with elevated RAD51 levels (P=0.052). In addition, RAD51 expression levels were highest in the skin keratinocytes, followed by the TSCCs and OMECs. Conclusion. A strong positive correlation was found between RAD51 expression and the degree of malignancy in OSCC patients, suggesting that RAD51 could be an excellent prognostic indicator for OSCC patients.

Nm23-H1 expression of metastatic tumors in the lymph nodes is a prognostic indicator of oral squamous cell carcinoma

2007 ◽  
Vol 122 (2) ◽  
pp. 377-386 ◽  
Author(s):  
Yi-Fen Wang ◽  
Jeou-Yuan Chen ◽  
Shyue-Yih Chang ◽  
Jen-Hwey Chiu ◽  
Wing-Yin Li ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Indicator ◽  
Metastatic Tumors
Sign in / Sign up

Export Citation Format

Share Document